NeuroDerm raises $67m in Nasdaq secondary offering

Oded Lieberman
Oded Lieberman

The Israeli company, which has developed a drug delivery system for treating Parkinson's, raised 16% more than planned.

Rehovot-based drug development company NeuroDerm(Nasdaq:NDRM) has raised $67 million in its Nasdaq secondary offering at a company value of $365 million. NeuroDerm has developed a system for subcutaneous delivery of drugs for treatment of diseases, mainly Parkinson's Disease, as a substitute for the current oral delivery of the drug.

With its share price of $17, the company raised 16% more than planned compared with the share price of $15.60 when its prospectus was filed with the US Securities and Exchange Commission (SEC). With underwriters options the offering could reach as high as $75.5 million, far higher than the planned $58 million. The underwriters for the current offering are Jeffreys and Cowen & Co and the accountants are PwC Israel.

NeuroDerm's shares rose 8.3% on Nasdaq yesterday to $17.13.

The company's impressive secondary offering comes eight months after NeuroDerm raised $45 million in its IPO at $10 per share.

Managed by CEO Oded Lieberman, NeuroDerm's principal shareholders are chairman Robert Taub (19%), Uwe Wascher (17%), and Prof. Shmuel Cabilly (15.5%). Taub, a resident of Belgium and an active investor in the Israeli biomedical sector, is a cofounder of Omrix Biopharmaceuticals, sold to Johnson & Johnson for $438 million.

Like NeuroDerm, Omrix also entered the stock exchange at a substantially lower value than it initially sought (only $143 million). Also like NeuroDerm, its share posted exceptional rises in its first year of trading, and the company was eventually sold at triple its IPO value. Wascher is a close friend of Taub; the two men also jointly invested in a number of companies, including Omrix. Cabilly, an Israeli, was a researcher at Genentech who discovered a patented drug that gained that company hundreds of millions of dollars in royalties. He is also an active investor in the Israeli biomedical sector.

The company's clinical plan is undertaking a trial against the oral drug with the appropriate dosage of the drug for patients with severe cases of Parkinson's in the first half of 2015. At the same time, a trial is underway to test only the levels of the product in the blood. Results are expected by the end of the year, after which a Phase III trial will be necessary. The company hopes its product will be approved in 2018.

Published by Globes [online], Israel business news - www.globes-online.com - on July 16, 2015

© Copyright of Globes Publisher Itonut (1983) Ltd. 2015

Oded Lieberman
Oded Lieberman
THAAD anti missile system credit: The US Army Ralph Scott Wikimedia Will US military aid to Israel stay solid under Trump?

Donald Trump refuses to fight other peoples' wars, and is looking to reduce the US presence in the Middle East.

Ibis Hotel Jerusalem inset Shlomo Dahokey credit: PR Hotel co Pie Siam completes TASE IPO

The company operates two Ibis Hotels in Jerusalem and a hotel in Tel Aviv with Isrotel and is building six more hotels.

Air India credit: Shutterstock Air India to resume Israel flights

Air India has announced the resumption of operations on the Tel Aviv-Delhi route starting March 2, 2025 with five weekly flights.

Turkish President Recep Tayyip Erdogan credit: Reuters Matt Rourke Turkey hints at end of Israel trade embargo

In the wake of the Gaza ceasefire, Turkish President Recep Tayyip Erdogan's focus has switched to Syria.

Eshkol power station credit: IEC Energean signs $2b Dalia power plants gas deal

Energean has signed a binding memorandum of understanding to provide 12 billion cubic meters of natural gas to Dalia Energy's Dalia and Eshkol power plants.

Shekel credit: Shutterstock Vladirina 32 Shekel strongest for two years against US dollar

Bank of America sees the Israeli currency continuing to strengthen if the ceasefire agreements are fully implemented.

Delta Airlines Credit: Michal Raz-Chaimovich Delta Airlines mulls resuming Israel flights before April

The announcement of the return of major European airlines to Israel including Lufthansa Group, Air France, British Airways and easyJet has increased the likelihood that US airlines will join the wave of resumptions and return to Israel.

Eleos founders credit: Omri Miron Israeli AI mental healthcare co Eleos raises $60m

The company is also announcing the launch of a powerful new clinical documentation improvement (CDI) product, Eleos Compliance.

Bank Leumi EVP Eyal Ben-Haim credit: Shlomi Yosef Bank Leumi EVP: The north will rebound in 2025

Bank Leumi EVP and head of banking division Eyal Ben-Haim told the "Return to the North" conference today that the north will recover and return to prosperity.

Mor Chen credit: Rory Lindsay Greylock appoints Mor Chen as Israel partner

The US venture capital fund is returning to Israel with local representation after more than a decade.

Ofra Strauss credit: Shlomi Yosef Ofra Strauss: New factory in north is our response

Strauss Group chairperson Ofra Strauss told the Globes "Returning to the North" conference that the company will open a new factory for plant-based products in Ahihud this year.

Moody's offices in Vilnius  credit: Shutterstock/Andrius Zemaitis As market prices rating upgrade, Treasury mulls o'seas offering

Officials from the Accountant General's Office have held meetings with financial institutions in London.

ICC-CAL CEO Levy Halevy credit: Rami Zarneger Credit card co ICC-CAL seeks NIS 4b valuation

Boosted by the bidding war for Isracard, the owners have hired investment bank J.P. Morgan to promote the sale of the company.

Benjamin Netanyahu and Bezalel Smotrich credit: Ronen Zvulun Reuters S&P, Fitch cautious on ceasefire's impact on Israel rating

Like Moody's, both credit rating agencies say the agreement with Hamas could alleviate the negative outlook for Israel, but that considerable uncertainty remains.

Amir Yaron  credit: Eyal Izhar BoI governor Yaron sees interest rate falling in second half

Amir Yaron told CNBC that one or two interest rate cuts were feasible in the second half of 2025 "as inflation is supposed to go into the target."

Aaron Frenkel credit: Eli Etkin Aaron Frenkel sells 2% Leumi stake

The Israeli businessman has recorded a 52% gain on the 31 million shares in the bank that he bought 30 months ago.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018